Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.32 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16294538 | 0.91 | LMNA (0.41) | MAPTSMN1; SMN2ALDH1A1L3MBTL1MEN1 | |
| SCHEMBL16294225 | 0.90 | LMNA (0.36) | MAPTSMN1; SMN2ALDH1A1L3MBTL1MEN1 | |
| SCHEMBL16294916 | 0.88 | CACNA1H (0.33) | MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL16293529 | 0.83 | GAA (0.36) | MAPTSMN1; SMN2ALDH1A1L3MBTL1MEN1 | |
| SCHEMBL16293439 | 0.82 | P2RX4 (0.32) | L3MBTL1MEN1KMT2A | |
| SCHEMBL16293461 | 0.82 | CYP19A1 (0.35) | — | |
| SCHEMBL16294666 | 0.81 | LMNA (0.30) | SMN1; SMN2LMNA | |
| SCHEMBL16293336 | 0.81 | ALDH1A1 (0.37) | MAPTSMN1; SMN2ALDH1A1L3MBTL1MEN1 | |
| SCHEMBL17700725 | 0.81 | LMNA (0.35) | MAPTSMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL17700765 | 0.81 | LMNA (0.42) | MAPTSMN1; SMN2ALDH1A1L3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9657006-B2 | Macrocyclic factor VIIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-23 | — | — | US | disclosed |
| US-20160115159-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160115159-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | F7, F12, F5 | MAPT 4625/4885SMN1; SMN2 2965/4885ALDH1A1 2603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.